<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629381</url>
  </required_header>
  <id_info>
    <org_study_id>2010-024338-43</org_study_id>
    <nct_id>NCT01629381</nct_id>
  </id_info>
  <brief_title>Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy</brief_title>
  <acronym>ERIKA</acronym>
  <official_title>Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective: To assess the value of Rivaroxaban for the prevention of venous&#xD;
      thromboembolism (VTE) after knee arthroscopy (KA) taking the placebo as standard of&#xD;
      reference.&#xD;
&#xD;
      Study Population: Patients undergoing therapeutic KA at the study Centers, irrespective of&#xD;
      the type and duration of the procedure, will be eligible for the study.&#xD;
&#xD;
      Study Design: Multicenter, randomized, double blind superiority, phase II trial comparing two&#xD;
      arms:&#xD;
&#xD;
        -  (R-7d) Rivaroxaban (10 mg od os) for 7 days&#xD;
&#xD;
        -  (PL-7d) Placebo for 7 days.&#xD;
&#xD;
      Follow-up: 3-month period after the randomization&#xD;
&#xD;
      Standard of Reference:Placebo will be the standard of reference in accordance to&#xD;
      international guidelines&#xD;
&#xD;
      Study length May 2012-December 2012&#xD;
&#xD;
      Total patients number: 500 patients&#xD;
&#xD;
      Primary Efficacy End-Point: Occurrence in the 3-month period after the randomization of at&#xD;
      least one of the following events, objectively proven (by means of CCDU; multi-slice chest&#xD;
      TC-angio; autopsy, if necessary, or clinical ground):&#xD;
&#xD;
        -  All-cause mortality&#xD;
&#xD;
        -  Symptomatic VTE&#xD;
&#xD;
        -  Asymptomatic proximal DVT&#xD;
&#xD;
      Secondary Efficacy End-point:&#xD;
&#xD;
      â€¢ Combined incidence of all DVT plus symptomatic PE&#xD;
&#xD;
      Primary Safety End-point: Incidence of major bleedings.&#xD;
&#xD;
      Secondary Safety End-point: Overall incidence of bleeding&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatments will be administered postoperatively (1st dose 8-10 hours after procedure),&#xD;
      for prevention of venous thromboembolism after KA.&#xD;
&#xD;
      A bilateral whole-leg colour-coded Doppler ultrasonography (CCDU) is scheduled for all&#xD;
      patients at 7 (+1) days of follow-up; additionally, CCDU was due if the patients developed&#xD;
      symptoms or signs suggestive of venous thromboembolism earlier.&#xD;
&#xD;
      Statistical &amp; Analytical Plan and Methodology: In the absence of prophylaxis the incidence of&#xD;
      venous thromboembolism (primary efficacy end-point) after KA, as assessed by CCDU, is about&#xD;
      8.0% (combining weighted results of various paper). Prophylaxis with low-molecular weight&#xD;
      heparins assures approximately a 60-70% relative risk reduction in this setting. Based on the&#xD;
      findings of published trials investigating the efficacy of Rivaroxaban for prevention of&#xD;
      venous thromboembolism after elective hip and knee surgery, when using a low-molecular-weight&#xD;
      heparin as comparator, investigators can speculate that Rivaroxaban will further reduce this&#xD;
      incidence (at least 1.2%).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Symptomatic Venous Thromboembolism Plus Asymptomatic Proximal Vein Thrombosis and All-cause Mortality</measure>
    <time_frame>3-month period</time_frame>
    <description>During the scheduled visit in case of suspected DVT a bilateral whole-leg colour-coded Doppler ultrasonography (CCDU) is scheduled for all patients at 7 (+1) days of follow-up; additionally, CCDU will be performed if the patients develop symptoms or signs suggestive of venous thromboembolism earlier; in case of suspected PE a multi-slice chest TC-angio is arranged; in case of death for all cause autoptic findings are requested or, if necessary, clinical ground is considered. A follow-up visit is planned 3-month period after the randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleedings</measure>
    <time_frame>3 months</time_frame>
    <description>Major bleeding include: clinically overt haemorrhage associated with haemoglobin drop of at least 2 g/L or requiring the transfusion of two or more units of packed red-blood cells; retroperitoneal or intracranial events; bleeding requiring re-intervention; and hemarthrosis with a joint drainage of more than 450 millilitres of blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined Incidence of All DVT Plus Symptomatic PE</measure>
    <time_frame>3 months</time_frame>
    <description>As described for the assessment of the primary efficacy outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Incidence of Bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>As described for the primary safety outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Rivaroxaban 10 mg od for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo od for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>10 mg os once daily for 1 week</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>10 mg os once daily for 1 week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patient (18 years and older)&#xD;
&#xD;
          2. Knee arthroscopy not combined with open surgery.&#xD;
&#xD;
          3. Patients eligible for surgical treatment.&#xD;
&#xD;
          4. Patients are willing and able to continue study participation to ensure completion of&#xD;
             all procedures and observations required by the study.&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnostic arthroscopy&#xD;
&#xD;
          2. Patients concomitantly treated systemically with strong concurrent CYP3A4 and&#xD;
             P-gp-inhibitors, i.e. azole-antimycotics or HIV protease inhibitors.&#xD;
&#xD;
          3. Hypersensitivity to the active substance or to any of the excipients of study drug&#xD;
&#xD;
          4. Pregnant women or breast-feeding.&#xD;
&#xD;
          5. Hepatic disease associated with coagulopathy and clinically relevant bleeding risk&#xD;
&#xD;
          6. Known thrombophilia (hereditary or acquired)&#xD;
&#xD;
          7. Mandatory anticoagulation.&#xD;
&#xD;
          8. Known severe bleeding tendency&#xD;
&#xD;
          9. Clinically significant active bleeding.&#xD;
&#xD;
         10. Severe renal failure (GFR&lt;30mL/min/1.73m2)&#xD;
&#xD;
         11. Patients participating in another clinical trial.&#xD;
&#xD;
         12. Recent mayor surgery (6 to 12 weeks)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Camporese, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Angiology, University Hospital of Padua, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thrombosis Center &amp; Knee Arthroscopy and Sports Medicine Center, Humanitas Clinical Insitute</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedics and Traumatology, University Hospital &quot;Galliera&quot; of Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, University Hospital of Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedics and Traumatology, University Hospital of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Section of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Hospital of Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit of Angiology, Department of Internal Medicine, Azienda Ospedaliera - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedics and Surgery of the Hand, Catholic University &quot;Sacro Cuore&quot;</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit of Angiology, Hospital of Venice</name>
      <address>
        <city>Venice</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://quovadis-ass.it/erika.html</url>
    <description>paper abstract and other informations</description>
  </link>
  <results_reference>
    <citation>Camporese G, Bernardi E, Noventa F, Bosco M, Monteleone G, Santoro L, Bortoluzzi C, Freguja S, Nardin M, Marullo M, Zanon G, Mazzola C, Damiani G, Maniscalco P, Imberti D, Lodigiani C, Becattini C, Tonello C, Agnelli G; ERIKA Study Group. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. Thromb Haemost. 2016 Aug 1;116(2):349-55. doi: 10.1160/TH16-02-0118. Epub 2016 Apr 14.</citation>
    <PMID>27075710</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <results_first_submitted>October 19, 2015</results_first_submitted>
  <results_first_submitted_qc>April 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2021</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Giuseppe Camporese</investigator_full_name>
    <investigator_title>MD, Principal Investigator, Coordinator of Emergency Section at the Unit of Angiology, University Hospital of Padua</investigator_title>
  </responsible_party>
  <keyword>knee arthroscopy</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between apr2012 and Mar2014, 1278 subjects were evaluated for inclusion. Of them, 241 (19%) subjects accepted to participate. Due to the unexpectedly low recruitment rate, being a spontaneous study, we were forced to stop the trial before reaching the planned sample size because we were not able to afford insurance costs anymore.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban</title>
          <description>Oral Rivaroxaban 10 mg od for 7 days&#xD;
Rivaroxaban: 10 mg os once daily for 1 week</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>oral placebo od for 7 days&#xD;
placebo: 10 mg os once daily for 1 week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban</title>
          <description>Oral Rivaroxaban 10 mg od for 7 days&#xD;
Rivaroxaban: 10 mg os once daily for 1 week</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>oral placebo od for 7 days&#xD;
placebo: 10 mg os once daily for 1 week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="12.8"/>
                    <measurement group_id="B2" value="45.9" spread="13.9"/>
                    <measurement group_id="B3" value="45.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Symptomatic Venous Thromboembolism Plus Asymptomatic Proximal Vein Thrombosis and All-cause Mortality</title>
        <description>During the scheduled visit in case of suspected DVT a bilateral whole-leg colour-coded Doppler ultrasonography (CCDU) is scheduled for all patients at 7 (+1) days of follow-up; additionally, CCDU will be performed if the patients develop symptoms or signs suggestive of venous thromboembolism earlier; in case of suspected PE a multi-slice chest TC-angio is arranged; in case of death for all cause autoptic findings are requested or, if necessary, clinical ground is considered. A follow-up visit is planned 3-month period after the randomization.</description>
        <time_frame>3-month period</time_frame>
        <population>Drop-out: seven randomized patients withdrew consent on the day of surgery, without taking the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Oral Rivaroxaban 10 mg od for 7 days&#xD;
Rivaroxaban: 10 mg os once daily for 1 week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oral placebo od for 7 days&#xD;
placebo: 10 mg os once daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Symptomatic Venous Thromboembolism Plus Asymptomatic Proximal Vein Thrombosis and All-cause Mortality</title>
          <description>During the scheduled visit in case of suspected DVT a bilateral whole-leg colour-coded Doppler ultrasonography (CCDU) is scheduled for all patients at 7 (+1) days of follow-up; additionally, CCDU will be performed if the patients develop symptoms or signs suggestive of venous thromboembolism earlier; in case of suspected PE a multi-slice chest TC-angio is arranged; in case of death for all cause autoptic findings are requested or, if necessary, clinical ground is considered. A follow-up visit is planned 3-month period after the randomization.</description>
          <population>Drop-out: seven randomized patients withdrew consent on the day of surgery, without taking the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Bleedings</title>
        <description>Major bleeding include: clinically overt haemorrhage associated with haemoglobin drop of at least 2 g/L or requiring the transfusion of two or more units of packed red-blood cells; retroperitoneal or intracranial events; bleeding requiring re-intervention; and hemarthrosis with a joint drainage of more than 450 millilitres of blood.</description>
        <time_frame>3 months</time_frame>
        <population>No major bleeding events were observed during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No major bleeding events were observed during the study period.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 10 mg for 7 Days</title>
            <description>No major bleeding events were observed during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleedings</title>
          <description>Major bleeding include: clinically overt haemorrhage associated with haemoglobin drop of at least 2 g/L or requiring the transfusion of two or more units of packed red-blood cells; retroperitoneal or intracranial events; bleeding requiring re-intervention; and hemarthrosis with a joint drainage of more than 450 millilitres of blood.</description>
          <population>No major bleeding events were observed during the study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Incidence of All DVT Plus Symptomatic PE</title>
        <description>As described for the assessment of the primary efficacy outcomes</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>oral placebo od for 7 days placebo: 10 mg os once daily for 1 week</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 10 mg for 7 Days</title>
            <description>Oral Rivaroxaban 10 mg od for 7 days Rivaroxaban: 10 mg os once daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Incidence of All DVT Plus Symptomatic PE</title>
          <description>As described for the assessment of the primary efficacy outcomes</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Incidence of Bleeding</title>
        <description>As described for the primary safety outcome</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>oral placebo od for 7 days placebo: 10 mg os once daily for 1 week</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 10 mg for 7 Days</title>
            <description>Oral Rivaroxaban 10 mg od for 7 days Rivaroxaban: 10 mg os once daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Incidence of Bleeding</title>
          <description>As described for the primary safety outcome</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days on therapy and 90 days of follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>oral placebo od for 7 days placebo: 10 mg os once daily for 1 week</description>
        </group>
        <group group_id="E2">
          <title>Rivaroxaban 10 mg for 7 Days</title>
          <description>Oral Rivaroxaban 10 mg od for 7 days Rivaroxaban: 10 mg os once daily for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>skin reaction</sub_title>
                <description>spontaneous, moderate, self-recovered skin reaction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Use of placebo instead of active comparator. Small sample size and quite high exclusion rate. Local events adjudication.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Giuseppe Camporese</name_or_title>
      <organization>University of Padua</organization>
      <phone>049 8212882 ext +39</phone>
      <email>giuseppe.camporese@aopd.veneto.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

